Houston regenerative medicine company opens new lab at UH

cell therapy innovation

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

From Your Site Articles
Space experts discussed the city's role in the space industry at a recent event. Photo via NASA

Overheard: Houston needs to strengthen infrastructure, workforce to maintain Space City status

eavesdropping in houston

In no time at all, humans will return to the moon and as they make the first spacewalks in fifty years — wearing suits designed in Houston — they will call down to earth, and only one city in the world will be named on the radio transmissions.

Houston is the Space City — but what will it take to maintain that moniker? This was a big topic of the Greater Houston Partnership's second annual State of Space event hosted on Tuesday, October 11.

A diverse and impressive panel discussed the Space City's future, the upcoming moon missions, commercializations, and more. If you missed the discussion, check out some key moments from the event.

"Houston has a significant role in all areas of Artemis."

— Vanessa Wyche, director of NASA's Johnson Space Center. "We have crew missions, robotic missions, and other technologies that will make up Artemis."

"The big mission we have is for Houston to remain the hub in human space flight moving forward."

— Wyche says, adding "for us to be the nexus and accelerator of research, innovation, and STEM, we need to work together for workforce development for the space economy."

"We're at a point were we can pivot to develop scalable products at a much lower cost — it really reduces the barrier of entry for commercial space partners."

— Peggy Guirgis, general manager of space systems for Collins Aerospace. "We're building in Houston because this is really an engineering hub," she adds, noting the industries and schools here that support the industry.

"Why Houston? Because of, more than anything, the sense of community."

— Steve Altemus, president and CEO of Intuitive Machines, noting the support behind building the Houston Spaceport and the existing Johnson Space Center, as well as all the other players within the space sector locally.

"At some point in the very near future we are going to land humans on the moon — the first woman on the moon, the first person of color on the moon — and we're going to say, 'Moon, Houston.' This is the only city in the world that's going to be said on those loops."

— Kate Rubins, NASA astronaut. "I feel very fortunate to be here."

"Right here in Houston — at the HoustonSpaceport, we're building a space where the Space Force can do classified work."

— Altemus says. "That's one area that I'd like to see grow."

"We need to continue to build a talent pipeline as well as generating a workforce that is able to keep pace with the rapidly growing space industry."

— Guirgis says.

"When people think about Houston, NASA has been the nexus and center of gravity, but all of Houston has been a magnet. It's a draw to come and work here."

— Rubins says. "One way to continue this is through infrastructure that's being built here — it's incredible. It's going to cement this as a place that you want to come if you're a commercial company and you want to partner with NASA, or you want to be a contractor for one of these other companies. ... And the startup scene is booming these days in Houston."

"We need to make sure that we have the world-class capabilities."

— Wyche says. "The workforce is so very important."

Here are three of the latest updates on new execs and advisory appointments from two Houston startups and a local venture group. Photo via Getty Images

3 Houston organizations announce strategic appointments across biotech and VC

short stories

Five Houston innovators have new roles they're excited about this spring. From new advisory board members to c-level execs, here's who's moving and shaking in Houston innovation.

The Artemis Fund names new vice president of finance and operations

Adrienne Mangual has a background in finance and consulting. Photo courtesy of Artemis

The Artemis Fund, a venture capital firm that funds female-founded startups with technology solutions in fintech, e-commerce tech, and care-tech, has announced a new member of its leadership.

Adrienne Mangual is the new vice president of finance and operations at the firm, joining Artemis's co-founders and general partners, Stephanie Campbell, Leslie Goldman, and Diana Murakhovskaya, along with Austin-based Juliette Richert, a senior analyst.

Mangual received her MBA from Rice University in 2019 after working 15 years in finance roles at J.P. Morgan and Key Energy Services. Over the past few years, she's worked in consulting positions with startups and technology.

"This is an exciting time to join The Artemis Fund as the fund is growing and our reach is expanding and continuing to make an impact on female founders," Mangual tells InnovationMap. "I am looking forward to supporting existing and future female founders and working with Diana, Stephanie, and Leslie as part of the team making investment decisions for the fund."

FibroBiologics appoints scientific advisory board member

Former astronaut Kate Rubins, who's spent a total of 300 days in space, has joined the a Houston company's scientific advisory board. Photo courtesy of FibroBiologics

Houston-based clinical-stage therapeutics company FibroBiologics announced the appointment of Kathleen “Kate” Rubins, Ph.D., to its scientific advisory board. A microbiologist and NASA astronaut, Rubins has conducted medical research on earth at academic institutions as well as on board the International Space Station.

“We are honored to welcome Dr. Rubins to our SAB,” says Pete O’Heeron, CEO and chairman of FibroBiologics, in a news release. “She has distinguished herself in both terrestrial research at the Salk and Whitehead Institutes and through her ethereal work on the International Space Station.

"It’s rare to have such a unique perspective on microbiology," he continues. "Dr. Rubins joins a board of world-renowned scientists who will help to guide us as we advance fibroblast cell-based therapeutics through preclinical and clinical development. We are the only company focused on this unique opportunity in leveraging fibroblasts as treatments for chronic diseases and Dr. Rubins will be a key advisor in our pursuit to bring relief to the patients.”

In 2016, Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. Most recently, she served on the ISS as a flight engineer for Expedition 63/64. Across her two flights, she has spent a total of 300 days in space, the fourth most days in space by a U.S. female astronaut, according to the release.

Cemvita Factory hires, promotes within its leadership team

Tara Karimi, co-founder and CTO, stands with Cemvita Factory's two new hires and recently promoted employee. Photo courtesy of Cemvita

Cemvita Factory has made big moves in its leadership team. The low-carbon biotech and synthetic biology solution provider has recently made three strategic appointments: Charles Nelson was hired as chief business officer, Roger A. Harris was promoted to chief commercial officer, and Alex Juminaga was recruited as head of strain development.

“Scaling to meet market demand requires the right team at the right time,” says Tara Karimi, co-founder and CTO of Cemvita, in a news release. “With Charlie, Roger, and Alex’s leadership, we’re well-positioned for growth at a time when the demand for decarbonization solutions is greater than ever.”

With over 10 years in product development, engineering, and technology commercialization experience, Nelson will oversee all aspects of sales, business development, and customer success.

“At Cemvita, we create sustainable solutions to challenges across heavy industries,” says Nelson in the release. “Our goal is to reinvent heavy industries in ways that speak to the future, reduce companies’ carbon footprints, and even create jobs; I’m delighted to help lead the charge.”

Harris originally joined Cemvita as vice president of technology commercialization a year ago and has over two decades of experience in research and development, and engineering. In his new role, he is responsible for scaling and commercializing the startup's technology.

“Cemvita is positioned incredibly well to support heavy industry in efforts to innovate, and to help oil and gas diversify offerings and reduce dependency on carbon-intensive products,” says Harris in the release. “It is an exciting time and I’m thrilled to be with Cemvita.”

Lastly, Alex Juminaga will lead the Cemvita biofoundry’s production of novel biomolecules. He brings over a decade of laboratory experience — specializing in metabolic engineering, protein expression/purification, enzyme kinetics and binding assays, analytical chemistry, and more.

“The field of synthetic biology is just getting started, with thousands of microbes yet to be discovered,” says Juminaga. “I’m excited to work alongside the brilliant scientists at Cemvita as we uncover new microbiomes and new uses for these tiny treasures.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston manufacturer names location of its $193.7 million facility

coming soon

Houston-based manufacturer of high-temperature superconducting wires MetOx International Inc. will build a major production facility in Chatham County, North Carolina, which is expected to create 333 jobs, and invest $193.7 million in the state.

MetOx is a leader in High Temperature Superconducting technology (HTS), which is an advanced power delivery technology that is capable of transmitting extremely high power at low voltage with zero heat generation or energy loss. The technology is assisting in the energy sectors like power transmission, distribution, and grid expansion.

“Establishing our new large-scale manufacturing facility in Chatham County is a pivotal step toward securing a reliable, domestic supply of HTS wire for the development of critical infrastructure in the United States,” Bud Vos, CEO of MetOx, says in a news release. “This facility will not only deliver transformative energy technologies that strengthen our grid and reduce carbon emissions but also create high-paying manufacturing jobs in a community eager to lead in innovation. We are proud to partner with North Carolina to drive forward a resilient energy future built on cutting-edge science and strong local collaboration.”

The new facility is funded in part by an $80 million investment from the United States Department of Energy, which the company announced in October. In September, the company closed $25 million in a series B extension round.

In late 2024, MetOx also announced that it received an undisclosed investment from Hawaii-based Elemental Impact, which is a leading climate-focused investment platform. As a national implementation partner for the EPA's $27 billion Greenhouse Gas Reduction Fund, Elemental Impact has received $100 million to deploy later-stage commercialized technologies according to the company.

The funding is expected to advance the expansion of MetOx’s Houston production line and the deployment of its HTS wire, which can make transmission cables up to ten times more efficient than traditional copper cables and will be used at the North Carolina facility.

“Building domestic manufacturing capacity for critical grid technologies is essential for America’s energy future," Danya Hakeem, vice president of Portfolio at Elemental Impact, says in a news release. “MetOx’s expansion in Houston demonstrates how we can simultaneously advance grid modernization and create quality manufacturing jobs. Their technology represents exactly the kind of innovation needed to unlock the next wave of clean energy deployment.”

The project in North Carolina will be facilitated with a Job Development Investment Grant formally awarded to a new company being created by MetOx. In the 12-year term of the grant, economists in the Department of Commerce estimated the project will grow North Carolina’s economy by $987.8 million.

------

This article originally was published on our sister site, EnergyCapital.

Houston Nobel Prize nominee earns latest award for public health research

Prized Research

Houston vaccine scientist Dr. Peter Hotez can add one more prize to his shelf.

Hotez — dean of the National School of Tropical Medicine and professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, co-director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics — is no stranger to impressive laurels. In 2022, he was even nominated for a Nobel Peace Prize for his low-cost COVID vaccine.

His first big win of 2025 is this year’s Hill Prize, awarded by the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Hotez and his team were selected to receive $500,000 from Lyda Hill Philanthropies to help fund The Texas Virosphere Project. The endeavor was born to help create a predictive disease atlas relating to climate disasters. Because the climate crisis has ushered in changes to the distribution of diseases, including dengue, chikungunya, Zika, Chagas disease, typhus and tick-borne relapsing fever, it’s important to predict outbreaks before they become a menace.

Rice University researchers are collaborating with Hotez and his team on a project that combines climate science and metagenomics to access 3,000 insect genomes. The goal is to aid health departments in controlling disease and informing policy.

The Hill Prize, which is being awarded to six innovators for the first time, thanks to a $10 million commitment from the philanthropic organization, is intended to back ideas that are high-risk and high-reward. Each of the projects was chosen for its potential real-life impact on some of Texas's — and the world’s — most challenging situations. Hotez’s prize is the first Hill Prize to be given in the realm of public health. The additional winners are:

  • Hill Prize in Medicine: Kenneth M. Hargreaves, D.D.S., Ph.D., The University of Texas Health Science Center at San Antonio
  • Hill Prize in Engineering: Joan Frances Brennecke, Ph.D. (NAE), The University of Texas at Austin
  • Hill Prize in Biological Sciences: David J. Mangelsdorf, Ph.D. (NAM, NAS), UT Southwestern Medical Center
  • Hill Prize in Physical Sciences: James Chelikowsky, Ph.D., The University of Texas at Austin
  • Hill Prize in Technology: Robert De Lorenzo, M.D., EmergenceMed, LLC
Read about other Houston-area researchers recognized by TAMEST here.

How Houston's cost of living compares to other major Texas cities in 2025

Calculating Costs

A new cost-of-living index yields a result that many Houstonians will find surprising: Houston is not the most expensive place to live in Texas. Dallas and Austin are costlier.

Numbeo’s cost-of-living index for 2025 shows Dallas ranks first in Texas and 24th in North America, landing at 65.8. The cost-of-living index compares the cost of living in New York City (which sits at 100) with the cost of living in another city. Austin is at 61.7, Houston at 60.6, and San Antonio at 58.8.

Houston ranks 40th overall in North America, out of 52 cities in the index.

Numbeo’s cost-of-living index takes into account the cost of items like groceries, restaurant meals, transportation, and utilities. The index excludes rent.

When rent is added to the cost-of-living index, Houston is still third among Texas cities. Dallas grabs the No. 21 spot in North America (57.1), one notch above Austin (56.6). Houston ranks 35th (51.4), and San Antonio ranks 42nd (34.6).

Rent index
While Dallas holds the top Texas spot on Numbeo’s overall cost-of-living index, Austin faces the highest rent prices. Numbeo's rent index for Austin sits at 50.1, putting it in 12th place among major cities in North America and highest in Texas, above the indexes for Dallas, Houston, and San Antonio. Houston lands at 27th.

The rent index in New York City, which tops the list, is 100. As Numbeo explains, the rent index estimates the cost of renting an apartment in a city compared with New York City. If the rent index is 50, for example, this suggests the average rent in that city is 50 percent below the average rent in New York City.

Around Texas, the rent index is:

  • 46.2 in Dallas
  • 39.8 in Houston
  • 34.6 in San Antonio

Restaurant index
In contrast to its showing on the rent and cost-of-living indexes, Houston outranks Dallas, Austin, and San Antonio on Numbeo’s restaurant index. This index compares the prices of meals and drinks at restaurants and bars to those in New York City.

Houston sits at No. 25 on the restaurant index, at 68.9. Dallas comes in at No. 32 (67.1), Austin at No. 34 (66.6), and San Antonio at No. 36 (65.2).

The National Restaurant Association reported in December that menu prices in the U.S. had risen 3.6 percent in the past 12 months, outpacing gains in grocery prices and the federal government’s overall Consumer Price Index. Fortunately for diners, that was the smallest 12-month increase in menu prices since August 2020, according to the association.

Toast, which provides a cloud-based restaurant management system, says the higher menu prices reflect higher food prices.

“Food prices have been increasing due to inflation, labor expenses, fuel costs, and supply chain disruptions, all of which impact restaurant profitability, Toast says. “While raising menu prices is one option to combat rising food costs, some restaurants have introduced service charges and simplified menus to avoid passing all costs onto customers.”

---

This story originally appeared on our sister site, CultureMap.com.

View All Listings